Wed Sep 10 05:50:00 UTC 2025: **Summary:**
Novo Nordisk, a Danish pharmaceutical company known for its diabetes and obesity treatments like Wegovy, is planning to cut approximately 9,000 jobs (around 11.5% of its workforce) as part of a company-wide restructuring effort. This move aims to simplify the organization, speed up decision-making, and focus resources on growth opportunities in the diabetes and obesity markets. The job cuts, with around 5,000 in Denmark, will result in a one-off cost of $1.26 billion, impacting the company’s full-year operating profit growth forecast. The restructuring comes after CEO Maziar Mike Doustdar took over last month and amid increased competition in the weight-loss drug market and disappointing trial results for a new obesity drug. The company’s shares initially dipped but recovered slightly following the announcement.
**News Article:**
**Novo Nordisk to Slash 9,000 Jobs in Restructuring Push**
COPENHAGEN – Danish pharmaceutical giant Novo Nordisk announced Wednesday it will cut approximately 9,000 jobs, representing around 11.5% of its global workforce, as part of a major restructuring initiative. The company, known for its diabetes and obesity treatments, including the popular Wegovy weight-loss medication, aims to streamline operations and sharpen its focus on key growth areas.
“Our markets are evolving, particularly in obesity, as it has become more competitive,” said CEO Maziar Mike Doustdar. “Our company must evolve as well. This means instilling an increased performance-based culture, deploying our resources ever more effectively, and prioritising investment where it will have the most impact.”
Approximately 5,000 of the job cuts are expected to occur in Denmark. The move will incur a one-time cost of 8 billion Danish kroner ($1.26 billion), leading Novo Nordisk to revise its full-year operating profit growth forecast downward to 4% to 10%, from the previously projected 10% to 16%.
The restructuring marks the first significant move under the leadership of Doustdar, who assumed the CEO role last month. He highlighted the need to defend Novo Nordisk’s leading position in diabetes and obesity treatment, foster a high-performance culture, and realign the company’s cost base as key priorities.
The announcement comes amid increased competition in the weight-loss drug market from rivals like Eli Lilly and compounded medications, as well as recent supply chain issues and disappointing trial results for Novo Nordisk’s next-generation obesity drug candidate, CagriSema.
Following the announcement, Novo Nordisk shares initially declined but recovered, trading up 2.5% in London as of 8:18 a.m. local time.
This is a developing story.
First Piper 